107 related articles for article (PubMed ID: 12353074)
1. Reduced factor V concentration and altered FV1/FV2 ratio do not fully explain R2-associated APC-resistance.
Govers-Riemslag JW; Castoldi E; Nicolaes GA; Tans G; Rosing J
Thromb Haemost; 2002 Sep; 88(3):444-9. PubMed ID: 12353074
[TBL] [Abstract][Full Text] [Related]
2. Functional properties of factor V and factor Va encoded by the R2-gene.
Hoekema L; Castoldi E; Tans G; Girelli D; Gemmati D; Bernardi F; Rosing J
Thromb Haemost; 2001 Jan; 85(1):75-81. PubMed ID: 11204592
[TBL] [Abstract][Full Text] [Related]
3. An assay to quantify the two plasma isoforms of factor V.
Hoekema L; Rosing J; Tans G
Thromb Haemost; 2000 Dec; 84(6):1066-71. PubMed ID: 11154115
[TBL] [Abstract][Full Text] [Related]
4. Factor V Has Anticoagulant Activity in Plasma in the Presence of TFPIα: Difference between FV1 and FV2.
van Doorn P; Rosing J; Duckers C; Hackeng TM; Simioni P; Castoldi E
Thromb Haemost; 2018 Jul; 118(7):1194-1202. PubMed ID: 29864781
[TBL] [Abstract][Full Text] [Related]
5. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.
Brugge JM; Simioni P; Bernardi F; Tormene D; Lunghi B; Tans G; Pagnan A; Rosing J; Castoldi E
J Thromb Haemost; 2005 Dec; 3(12):2695-702. PubMed ID: 16359508
[TBL] [Abstract][Full Text] [Related]
6. The R2-haplotype associated Asp2194Gly mutation in the light chain of human factor V results in lower expression levels of FV, but has no influence on the glycosylation of Asn2181.
van der Neut Kolfschoten M; Dirven RJ; Vos HL; Bertina RM
Thromb Haemost; 2003 Mar; 89(3):429-37. PubMed ID: 12624624
[TBL] [Abstract][Full Text] [Related]
7. Determination of activated protein C resistance in anticoagulated and lupus positive patients.
Ivey LM; Thom JY; Ivey JG; Baker RI
Blood Coagul Fibrinolysis; 2000 Jul; 11(5):439-45. PubMed ID: 10937805
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma.
Castoldi E; Rosing J; Girelli D; Hoekema L; Lunghi B; Mingozzi F; Ferraresi P; Friso S; Corrocher R; Tans G; Bernardi F
Thromb Haemost; 2000 Mar; 83(3):362-5. PubMed ID: 10744138
[TBL] [Abstract][Full Text] [Related]
9. Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.
Cramer TJ; Griffin JH; Gale AJ
Pathophysiol Haemost Thromb; 2010; 37(1):17-23. PubMed ID: 20501981
[TBL] [Abstract][Full Text] [Related]
10. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations.
Castoldi E; Brugge JM; Nicolaes GA; Girelli D; Tans G; Rosing J
Blood; 2004 Jun; 103(11):4173-9. PubMed ID: 14976057
[TBL] [Abstract][Full Text] [Related]
11. The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance.
Chitolie A; Lawrie AS; Mackie IJ; Harrison P; Machin SJ
Blood Coagul Fibrinolysis; 2001 Apr; 12(3):179-86. PubMed ID: 11414631
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
Aparicio C; Dahlbäck B
Biochem J; 1996 Jan; 313 ( Pt 2)(Pt 2):467-72. PubMed ID: 8573079
[TBL] [Abstract][Full Text] [Related]
13. Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes.
Segers O; Simioni P; Tormene D; Bulato C; Gavasso S; Rosing J; Castoldi E
J Thromb Haemost; 2012 Jan; 10(1):73-80. PubMed ID: 22044617
[TBL] [Abstract][Full Text] [Related]
14. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Dahlbäck B
Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of three reactants for the detection of activated protein C resistance due to mutation of factor V Leiden during pregnancy].
Magdelaine A; Soubrier F; Berkane N; Uzan S; Verdy E
Ann Biol Clin (Paris); 1998; 56(4):445-50. PubMed ID: 9754280
[TBL] [Abstract][Full Text] [Related]
16. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.
Heeb MJ; Kojima Y; Greengard JS; Griffin JH
Blood; 1995 Jun; 85(12):3405-11. PubMed ID: 7780127
[TBL] [Abstract][Full Text] [Related]
17. The activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model.
van der Neut Kolfschoten M; Dirven RJ; Tans G; Rosing J; Vos HL; Bertina RM
Blood Coagul Fibrinolysis; 2002 Apr; 13(3):207-15. PubMed ID: 11943934
[TBL] [Abstract][Full Text] [Related]
18. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM
Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320
[TBL] [Abstract][Full Text] [Related]
19. Plasma homocysteine concentration is not associated with activated protein C resistance in patients investigated for hypercoagulability.
Zarychanski R; Houston DS
Thromb Haemost; 2004 Jun; 91(6):1115-22. PubMed ID: 15175797
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of recombinant FV Hong Kong and FV Cambridge.
Norstrøm E; Thorelli E; Dahlbäck B
Blood; 2002 Jul; 100(2):524-30. PubMed ID: 12091344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
